ESBATech, now a Novartis company, is recognized for its pioneering role in developing single-chain antibody fragments for ophthalmic indications. The most advanced product from the ESBATech platform received market approval by the FDA in October 2019 and shortly thereafter in all major markets.

  • Nominated in 2020
  • Winner in 2021